SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ArQule
ARQL 20.000.0%Jan 16 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tommysdad who wrote (333)5/12/1999 9:25:00 PM
From: StockDoc  Read Replies (1) of 399
 
Entering preclinical tox studies indicates that the molecule(s) is manufactured under cGMP in and is going to be tested in people assuming that the PK/PD is favorable. Oherwise it is not a big deal - for Roche - indeed. For ArQule, this is the final deal or final product - i.e., big deal. They would need such things by the dozen to become what they wanted to be.
No molecule is worth $100 M before clinical testing.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News